Considerations for safety in the use of systemic medications for psoriasis and atopic dermatitis during the COVID-19 pandemic
© 2020 Wiley Periodicals LLC..
Coronavirus disease 2019 (COVID-19) is responsible for at least 2 546 527 cases and 175 812 deaths as of April 21, 2020. Psoriasis and atopic dermatitis (AD) are common, chronic, inflammatory skin conditions, with immune dysregulation as a shared mechanism; therefore, mainstays of treatment include systemic immunomodulating therapies. It is unknown whether these therapies are associated with increased COVID-19 susceptibility or worse outcomes in infected patients. In this review, we discuss overall infection risks of nonbiologic and biologic systemic medications for psoriasis and AD and provide therapeutic recommendations. In summary, in patients with active infection, systemic conventional medications, the Janus kinase inhibitor tofacitinib, and biologics for psoriasis should be temporarily held until there is more data; in uninfected patients switching to safer alternatives should be considered. Interleukin (IL)-17, IL-12/23, and IL-23 inhibitors are associated with low infection risk, with IL-17 and IL-23 favored over IL-12/23 inhibitors. Pivotal trials and postmarketing data also suggest that IL-17 and IL-23 blockers are safer than tumor necrosis factor alpha blockers. Apremilast, acitretin, and dupilumab have favorable safety data and may be safely initiated and continued in uninfected patients. Without definitive COVID-19 data, these recommendations may be useful in guiding treatment of psoriasis and AD patients during the COVID-19 pandemic.
Medienart: |
E-Artikel |
---|
Erscheinungsjahr: |
2020 |
---|---|
Erschienen: |
2020 |
Enthalten in: |
Zur Gesamtaufnahme - volume:33 |
---|---|
Enthalten in: |
Dermatologic therapy - 33(2020), 5 vom: 07. Sept., Seite e13687 |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Ricardo, Jose W [VerfasserIn] |
---|
Links: |
---|
Themen: |
Atopic dermatitis |
---|
Anmerkungen: |
Date Completed 23.12.2020 Date Revised 16.07.2022 published: Print-Electronic Citation Status MEDLINE |
---|
doi: |
10.1111/dth.13687 |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
NLM310405475 |
---|
LEADER | 01000naa a22002652 4500 | ||
---|---|---|---|
001 | NLM310405475 | ||
003 | DE-627 | ||
005 | 20231225140023.0 | ||
007 | cr uuu---uuuuu | ||
008 | 231225s2020 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.1111/dth.13687 |2 doi | |
028 | 5 | 2 | |a pubmed24n1034.xml |
035 | |a (DE-627)NLM310405475 | ||
035 | |a (NLM)32458536 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
100 | 1 | |a Ricardo, Jose W |e verfasserin |4 aut | |
245 | 1 | 0 | |a Considerations for safety in the use of systemic medications for psoriasis and atopic dermatitis during the COVID-19 pandemic |
264 | 1 | |c 2020 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a ƒaComputermedien |b c |2 rdamedia | ||
338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
500 | |a Date Completed 23.12.2020 | ||
500 | |a Date Revised 16.07.2022 | ||
500 | |a published: Print-Electronic | ||
500 | |a Citation Status MEDLINE | ||
520 | |a © 2020 Wiley Periodicals LLC. | ||
520 | |a Coronavirus disease 2019 (COVID-19) is responsible for at least 2 546 527 cases and 175 812 deaths as of April 21, 2020. Psoriasis and atopic dermatitis (AD) are common, chronic, inflammatory skin conditions, with immune dysregulation as a shared mechanism; therefore, mainstays of treatment include systemic immunomodulating therapies. It is unknown whether these therapies are associated with increased COVID-19 susceptibility or worse outcomes in infected patients. In this review, we discuss overall infection risks of nonbiologic and biologic systemic medications for psoriasis and AD and provide therapeutic recommendations. In summary, in patients with active infection, systemic conventional medications, the Janus kinase inhibitor tofacitinib, and biologics for psoriasis should be temporarily held until there is more data; in uninfected patients switching to safer alternatives should be considered. Interleukin (IL)-17, IL-12/23, and IL-23 inhibitors are associated with low infection risk, with IL-17 and IL-23 favored over IL-12/23 inhibitors. Pivotal trials and postmarketing data also suggest that IL-17 and IL-23 blockers are safer than tumor necrosis factor alpha blockers. Apremilast, acitretin, and dupilumab have favorable safety data and may be safely initiated and continued in uninfected patients. Without definitive COVID-19 data, these recommendations may be useful in guiding treatment of psoriasis and AD patients during the COVID-19 pandemic | ||
650 | 4 | |a Journal Article | |
650 | 4 | |a Review | |
650 | 4 | |a COVID-19 | |
650 | 4 | |a atopic dermatitis | |
650 | 4 | |a biologics | |
650 | 4 | |a immunosuppression | |
650 | 4 | |a psoriasis | |
650 | 7 | |a Immunologic Factors |2 NLM | |
650 | 7 | |a Interleukin-17 |2 NLM | |
650 | 7 | |a Interleukin-23 |2 NLM | |
650 | 7 | |a Janus Kinase Inhibitors |2 NLM | |
650 | 7 | |a Tumor Necrosis Factor-alpha |2 NLM | |
700 | 1 | |a Lipner, Shari R |e verfasserin |4 aut | |
773 | 0 | 8 | |i Enthalten in |t Dermatologic therapy |d 1998 |g 33(2020), 5 vom: 07. Sept., Seite e13687 |w (DE-627)NLM096394870 |x 1529-8019 |7 nnns |
773 | 1 | 8 | |g volume:33 |g year:2020 |g number:5 |g day:07 |g month:09 |g pages:e13687 |
856 | 4 | 0 | |u http://dx.doi.org/10.1111/dth.13687 |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a GBV_NLM | ||
951 | |a AR | ||
952 | |d 33 |j 2020 |e 5 |b 07 |c 09 |h e13687 |